Skip Navigation

Rheumatology 2006 45(1):9-10; doi:10.1093/rheumatology/kei237
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Glück, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glück, T.
Related Collections
Right arrow Health Economics
Right arrow Systemic Lupus Erythematosus and Autoimmunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

EDITORIAL

Vaccinate your immunocompromised patients!

T. Glück

Klinikum der Universität Regensburg, Franz-Josef-Strauss-Allee, 93042 Regensburg, Germany

Correspondence to: thomas.glueck@klinik.uni-regensburg.de

The first 10% of the full text of this article appears below.

Patients with rheumatoid arthritis and other chronic rheumatic diseases are at approximately doubled risk of infection compared with the normal population [1]. This may be in part due to still ill-defined immunoregulatory abnormalities associated with rheumatic diseases, but is certainly in large part secondary to the immunosuppressive therapy administered to these patients in the best interest of their joints, with proven efficacy in delaying joint destruction. The effect of disease-modifying therapies on the immune system, however, may be quite dramatic, especially if aggressive protocols such as Fauci's are administered, and they may lead to opportunistic infections otherwise only seen in patients with advanced HIV infection [2]. Inhibition of lymphocyte . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
A. Holvast, S. van Assen, A. de Haan, A. Huckriede, C. A. Benne, J. Westra, A. Palache, J. Wilschut, C. G. M. Kallenberg, and M. Bijl
Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study
Rheumatology, October 1, 2009; 48(10): 1294 - 1299.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J. Pradeep, R. Watts, and G. Clunie
Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis
Ann Rheum Dis, June 1, 2007; 66(6): 837 - 838.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. Doe, S. Pathare, C. A. Kelly, C. R. Heycock, J. Binding, and J. Hamilton
Uptake of influenza vaccination in patients on immunosuppressant agents for rheumatological diseases: a follow-up audit of the influence of secondary care
Rheumatology, April 1, 2007; 46(4): 715 - 716.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
W. A. Fahy, E. Farnworth, K. P. Yeldrem, G. S. Melling, and D. M. Grennan
Pneumococcal and influenza vaccination in patients with rheumatic conditions and receiving DMARD therapy
Rheumatology, July 1, 2006; 45(7): 912 - 913.
[Full Text] [PDF]

Home page
 BMJHome page
Minerva
BMJ, February 11, 2006; 332(7537): 372 - 372.
[Full Text] [PDF]